The combination of AFM13 with AlloNK has been granted FDA fast track designation and is being investigated in the phase 2 LuminICE-203 study for patients with Hodgkin lymphoma.
The FDA has granted fast track designation to the combination of AFM13 with AlloNK (AB-101) for the potential treatment of patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL), according to Affimed N.V.1
AFM13 is a first-in-class innate cell engager (ICE) designed to activate the immune system’s natural killer cells and macrophages and destroy CD30-positive cancer cells. AlloNK is a non-genetically modified, cord blood–derived, allogeneic, cryopreserved, antibody dependent cellular cytotoxicity that enhances NK cell therapy. The product is designed for use in combination with monoclonal antibodies or ICE agents in the outpatient setting.
The combination is currently being evaluated in the phase 2 LuminICE-203 study (NCT05883449) for this patient population, for which the trial received investigational new drug-clearance from the FDA earlier this year in March 2023.
“Our clinical data of AFM13 in combination with allogeneic NK cells has shown outstanding efficacy and a well-managed safety profile in late-stage, muti-refractory patients with relapsed/refractory Hodgkin and non-Hodgkin lymphoma,” said Wolfgang Fischer, PhD, chief operating officer at Affimed, in a press release. “The FDA fast track designation is a testament to the powerful potential our combination approach may deliver for these patients in high need, and we remain committed to working closely with the FDA to expedite development of this important therapy.”
In the phase 2, open-label, multi-cohort LuminICE-203 trial, the efficacy and safety of AFM13 with AB-101 will be evaluated for the treatment of patients with relapsed/refractory classical Hodgkin lymphoma. There will also be an exploratory cohort evaluating the combination in 20 patients with CD30-positive peripheral T-cell lymphoma (PTCL).2
The study will include a safety run-in followed by dose optimization, and dose-expansion phases. Approximately 24 patients with HL will be included in the safety run-in phase, along with 68 in the dose optimization and 110 in the dose-expansion phases.
Enrollment is open to patients 18 years of age and older with HL who have received at least 2 prior lines of therapy, including 1 which must have consisted of chemotherapy, brentuximab vedotin (Adcetris), and a PD-1 inhibitor.
The primary end point of the study is objective response rate (ORR). Secondary end points being evaluated include efficacy, durability of response, safety and tolerability, and immunogenicity.
This study builds on the findings from the phase 1/2 AFM13-104 trial (NCT04074746) of AFM13 in combination with cord blood-derived natural killer cells in heavily pretreated patients with CD30-positive HL and non-HL.1
According to findings from this study, patients with late-stage, multi-refractory disease had an ORR of 94% and a complete response (CR) rate of 71%. In the 31 patients with R/R HL, the ORR and CR rates were 97% and 77%, respectively.
The safety profile of the combination was well-managed when given at the recommended phase 2 dose.